• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

异柠檬酸脱氢酶（IDH）抑制剂时代，IDH1/2突变的骨髓增殖性肿瘤后急性髓系白血病（AML）患者的预后

Outcome of patients with IDH1/2-mutated post-myeloproliferative neoplasm AML in the era of IDH inhibitors.

作者信息

Chifotides Helen T, Masarova Lucia, Alfayez Mansour, Daver Naval, Alvarado Yesid, Jabbour Elias, Konopleva Marina, Kantarjian Hagop M, Patel Keyur P, DiNardo Courtney D, Verstovsek Srdan

机构信息

Department of Leukemia and.

Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX.

出版信息

Blood Adv. 2020 Nov 10;4(21):5336-5342. doi: 10.1182/bloodadvances.2020001528.

DOI:10.1182/bloodadvances.2020001528
PMID:33112940
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7656917/
Abstract

IDH1/2-inhibitor–based combinations conferred significant clinical responses in patients with -mutated post–MPN AML. Complete remission was achieved in 3/7 patients (1 attaining MRD–) with new -mutated post–MPN AML treated with IDH1/2-i combinations.

摘要

基于异柠檬酸脱氢酶1/2（IDH1/2）抑制剂的联合治疗方案在伴有IDH1/2突变的骨髓增殖性肿瘤（MPN）后继发性急性髓系白血病（AML）患者中产生了显著的临床反应。在7例接受IDH1/2抑制剂联合治疗的伴有新发生IDH1/2突变的MPN后继发性AML患者中，有3例（1例达到微小残留病阴性）实现了完全缓解。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2226/7656917/9f5ded20a913/advancesADV2020001528absf1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2226/7656917/9f5ded20a913/advancesADV2020001528absf1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2226/7656917/9f5ded20a913/advancesADV2020001528absf1.jpg

相似文献

1
Outcome of patients with IDH1/2-mutated post-myeloproliferative neoplasm AML in the era of IDH inhibitors.异柠檬酸脱氢酶（IDH）抑制剂时代，IDH1/2突变的骨髓增殖性肿瘤后急性髓系白血病（AML）患者的预后
Blood Adv. 2020 Nov 10;4(21):5336-5342. doi: 10.1182/bloodadvances.2020001528.
2
Combining Isocitrate Dehydrogenase Inhibitors With Existing Regimens in Acute Myeloid Leukemia: An Evolving Treatment Landscape.联合异柠檬酸脱氢酶抑制剂与现有的治疗方案治疗急性髓系白血病：不断发展的治疗领域。
Cancer J. 2022;28(1):21-28. doi: 10.1097/PPO.0000000000000570.
3
Isocitrate dehydrogenase (IDH) inhibition as treatment of myeloid malignancies: Progress and future directions.异柠檬酸脱氢酶（IDH）抑制作为治疗髓系恶性肿瘤的方法：进展与未来方向。
Pharmacol Ther. 2017 Sep;177:123-128. doi: 10.1016/j.pharmthera.2017.03.003. Epub 2017 Mar 14.
4
IDH Inhibitors in AML-Promise and Pitfalls.IDH 抑制剂在 AML 中的应用：前景与挑战。
Curr Hematol Malig Rep. 2021 Apr;16(2):207-217. doi: 10.1007/s11899-021-00619-3. Epub 2021 Apr 30.
5
Outcome of relapsed/refractory AML patients with IDH1 mutations in real life before the era of IDH1 inhibitors.在异柠檬酸脱氢酶1（IDH1）抑制剂时代之前，现实生活中IDH1突变的复发/难治性急性髓系白血病（AML）患者的结局。
Leuk Lymphoma. 2020 Feb;61(2):473-476. doi: 10.1080/10428194.2019.1668937. Epub 2019 Sep 30.
6
Outcomes for Patients With IDH-Mutated Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation.异柠檬酸脱氢酶突变型急性髓系白血病患者接受异基因造血细胞移植的结局。
Transplant Cell Ther. 2021 Jun;27(6):479.e1-479.e7. doi: 10.1016/j.jtct.2021.02.028. Epub 2021 Feb 25.
7
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.ivosidenib 治疗 IDH1 突变复发性或难治性 AML 的持久缓解。
N Engl J Med. 2018 Jun 21;378(25):2386-2398. doi: 10.1056/NEJMoa1716984. Epub 2018 Jun 2.
8
Pretreatment d-2-hydroxyglutarate serum levels negatively impact on outcome in IDH1-mutated acute myeloid leukemia.治疗前 d-2-羟戊二酸血清水平对 IDH1 突变型急性髓系白血病的预后有负面影响。
Leukemia. 2016 Apr;30(4):782-8. doi: 10.1038/leu.2015.317. Epub 2015 Nov 19.
9
Isocitrate dehydrogenase 1 mutations prime the all-trans retinoic acid myeloid differentiation pathway in acute myeloid leukemia.异柠檬酸脱氢酶1突变引发急性髓系白血病中全反式维甲酸髓系分化途径。
J Exp Med. 2016 Apr 4;213(4):483-97. doi: 10.1084/jem.20150736. Epub 2016 Mar 7.
10
Therapeutic targeting of isocitrate dehydrogenase mutant AML.异柠檬酸脱氢酶突变型急性髓系白血病的治疗靶点
Expert Opin Investig Drugs. 2017 May;26(5):525-530. doi: 10.1080/13543784.2017.1317745. Epub 2017 Apr 19.

引用本文的文献

1
Chromothripsis-associated chromosome 21 amplification orchestrates transformation to blast-phase MPN through targetable overexpression of DYRK1A.染色体碎裂相关的21号染色体扩增通过可靶向的DYRK1A过表达调控向急变期骨髓增殖性肿瘤的转化。
Nat Genet. 2025 Jun;57(6):1478-1492. doi: 10.1038/s41588-025-02190-6. Epub 2025 Jun 9.
2
Real World Management of Cytopenias and Infections in Patients With Myelofibrosis Treated With Ruxolitinib.芦可替尼治疗的骨髓纤维化患者血细胞减少和感染的真实世界管理
EJHaem. 2025 Mar 21;6(2):e70007. doi: 10.1002/jha2.70007. eCollection 2025 Apr.
3
SOHO State of the Art Updates and Next Questions | Challenging Scenarios in the Management of Myeloproliferative Neoplasms.

本文引用的文献

1
Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia.突变型异柠檬酸脱氢酶 1 抑制剂伊维替尼联合阿扎胞苷治疗新诊断的急性髓系白血病。
J Clin Oncol. 2021 Jan 1;39(1):57-65. doi: 10.1200/JCO.20.01632. Epub 2020 Oct 29.
2
Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study.ivosidenib 或enasidenib 联合强化化疗治疗初诊 AML 患者的 1 期研究。
Blood. 2021 Apr 1;137(13):1792-1803. doi: 10.1182/blood.2020007233.
3
Leukemia secondary to myeloproliferative neoplasms.
SOHO最新技术进展与后续问题 | 骨髓增殖性肿瘤管理中的挑战性病例
Clin Lymphoma Myeloma Leuk. 2025 Jul;25(7):484-493. doi: 10.1016/j.clml.2025.02.003. Epub 2025 Feb 16.
4
Olutasidenib demonstrates significant clinical activity in mutated IDH1 acute myeloid leukaemia arising from a prior myeloproliferative neoplasm.奥拉帕尼在先前骨髓增殖性肿瘤引起的IDH1突变急性髓系白血病中显示出显著的临床活性。
Br J Haematol. 2025 Apr;206(4):1121-1128. doi: 10.1111/bjh.19944. Epub 2024 Dec 19.
5
Prevention and treatment of transformation of myeloproliferative neoplasms to acute myeloid leukemia.骨髓增殖性肿瘤转化为急性髓系白血病的防治
Haematologica. 2025 Apr 1;110(4):828-839. doi: 10.3324/haematol.2023.283950. Epub 2024 Oct 24.
6
How I treat secondary acute myeloid leukemia.我如何治疗继发性急性髓系白血病。
Blood. 2025 Mar 20;145(12):1260-1272. doi: 10.1182/blood.2024024011.
7
Clinical Implications of Isocitrate Dehydrogenase Mutations and Targeted Treatment of Acute Myeloid Leukemia with Mutant Isocitrate Dehydrogenase Inhibitors-Recent Advances, Challenges and Future Prospects.异柠檬酸脱氢酶突变的临床意义及突变型异柠檬酸脱氢酶抑制剂靶向治疗急性髓系白血病的最新进展、挑战与未来前景。
Int J Mol Sci. 2024 Jul 19;25(14):7916. doi: 10.3390/ijms25147916.
8
Treatment approach and outcomes of patients with accelerated/blast-phase myeloproliferative neoplasms in the current era.当代加速/急变期骨髓增殖性肿瘤患者的治疗方法和结局。
Blood Adv. 2024 Jul 9;8(13):3468-3477. doi: 10.1182/bloodadvances.2024012880.
9
Final phase 1 substudy results of ivosidenib for patients with mutant IDH1 relapsed/refractory myelodysplastic syndrome.ivosidenib 治疗 IDH1 突变复发/难治性骨髓增生异常综合征患者的最终 1 期亚组研究结果。
Blood Adv. 2024 Aug 13;8(15):4209-4220. doi: 10.1182/bloodadvances.2023012302.
10
Treating accelerated and blast phase myeloproliferative neoplasms: progress and challenges.治疗加速期和急变期骨髓增殖性肿瘤：进展与挑战
Ther Adv Hematol. 2023 Jun 22;14:20406207231177282. doi: 10.1177/20406207231177282. eCollection 2023.
继发于骨髓增生性肿瘤的白血病。
Blood. 2020 Jul 2;136(1):61-70. doi: 10.1182/blood.2019000943.
4
Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML.介导异柠檬酸脱氢酶1（IDH1）突变的复发或难治性急性髓系白血病（AML）患者接受艾伏尼布单药治疗后复发的分子机制。
Blood Adv. 2020 May 12;4(9):1894-1905. doi: 10.1182/bloodadvances.2020001503.
5
Clinical outcomes of IDH2-mutated advanced-phase Ph-negative myeloproliferative neoplasms treated with enasidenib.使用恩西地平治疗异柠檬酸脱氢酶2（IDH2）突变的晚期阴性费城染色体骨髓增殖性肿瘤的临床结果
Br J Haematol. 2020 Jul;190(1):e48-e51. doi: 10.1111/bjh.16709. Epub 2020 May 1.
6
A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia.鲁索替尼与地西他滨治疗骨髓增殖性肿瘤后急性髓系白血病患者的1/2期研究。
Leukemia. 2020 Sep;34(9):2489-2492. doi: 10.1038/s41375-020-0778-0. Epub 2020 Feb 25.
7
Venetoclax for AML: changing the treatment paradigm.维奈托克治疗急性髓系白血病：改变治疗模式。
Blood Adv. 2019 Dec 23;3(24):4326-4335. doi: 10.1182/bloodadvances.2019000937.
8
Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia.ivosidenib 可诱导新诊断的 IDH1 突变型急性髓系白血病患者深度持久缓解。
Blood. 2020 Feb 13;135(7):463-471. doi: 10.1182/blood.2019002140.
9
How I treat acute myeloid leukemia in the era of new drugs.如何在新药时代治疗急性髓系白血病。
Blood. 2020 Jan 9;135(2):85-96. doi: 10.1182/blood.2019001239.
10
Prognostic impact of RAS-pathway mutations in patients with myelofibrosis.RAS 通路突变对骨髓纤维化患者预后的影响。
Leukemia. 2020 Mar;34(3):799-810. doi: 10.1038/s41375-019-0603-9. Epub 2019 Oct 18.